Hormone Therapy News

NEW ORLEANS — Three new testosterone therapies offer innovative drug delivery options for men with hypogonadism that improve patient satisfaction while avoiding risks related to secondary exposure, according to several speakers at the Androgen Society annual meeting.

NEW ORLEANS — Men with obesity and hypogonadism who underwent testosterone therapy achieved greater 10-year weight loss and experienced protective effects against cardiovascular and mortality risks compared with similar men who did not receive testosterone, according to findings presented at the Endocrine Society Annual Meeting.

NEW ORLEANS — Healthy men who used nonprescribed androgens to improve athletic performance experienced a slow recovery of suppressed testicular function after stopping drug use, with time to recovery ranging from 9 to 18 months, according to findings presented at the Endocrine Society annual meeting.

NEW ORLEANS — Long-term testosterone therapy may not only help men with obesity and hypogonadism to lose weight, but it may have other useful effects on metabolic function and protect against obesity comorbidities, according to a presentation at the Androgen Society annual meeting.

NEW ORLEANS — Medical advancements have come a long way in the past century, but it is in the next 80 years that we may see tremendous breakthroughs in eliminating human disease — at least that is the goal for the Chan Zuckerberg Initiative.

NEW ORLEANS — Healthy men assigned to a daily oral modified testosterone pill for 1 month experienced a decrease in serum testosterone consistent with effective contraception while maintaining androgenic traits such as sexual function, according to study data presented at the Endocrine Society annual meeting.

NEW ORLEANS — At least 1 year of testosterone therapy did not reduce anti-Müllerian hormone levels or antral follicular count in a cohort of transgender men in Israel, providing evidence for preserved ovarian reserve, according to data presented at The Endocrine Society Annual Meeting.

NEW ORLEANS — Low-dose human chorionic gonadotropin, or hCG, may preserve spermatogenesis in men with hypogonadism treated with intramuscular or transdermal testosterone replacement therapy, according to a speaker at the Androgen Society annual meeting.

NEW ORLEANS — Premenopausal and postmenopausal women reporting a persistent, low libido that profoundly impairs quality of life can experience an improvement in symptoms with transdermal testosterone, but clinicians must consider several important points before prescribing the therapy, according to a speaker at the Androgen Society annual meeting.

A memorandum signed by the U.S. Department of Defense on Tuesday will effectively bar transgender service members who seek cross-sex hormone therapy or gender-confirming surgeries from military service, following a July announcement by President Donald Trump that has led to numerous legal challenges.